
What is claimed is:

1. A compound having the general formula **I**



I

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is $hetAr^1(CH_2)_m$-, $hetAr^2CH_2$-, $hetAr^3CH_2$-, (3-6C cycloalkyl)-CH_2-, $hetCyc^1CH_2$-, $Ar^1(CH_2)_n$- or (N-1-3C alkyl)pyridinonyl-CH_2-;

$hetAr^1$ is a 6-membered heteroaryl having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, (1-4C)alkoxy, halogen, CF_3, or (3-6C)cycloalkyl;

m is 0, 1 or 2;

$hetAr^2$ is a 5-membered heteroaryl ring having 2-3 ring heteroatoms independently selected from N and S where at least one of said heteroatoms is N, wherein said ring is optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetAr^3$ is a bicyclic 5,6-fused heteroaryl ring having two ring nitrogen atoms;

$hetCyc^1$ is a 6-membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with -C(=O)(1-6C alkyl) or -C(=O)O(1-6C alkyl);

Ar^1 is phenyl optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkyl, CN, CF_3, OH, (1-6C)alkoxy, -C(=O)OH, -C(=O)O(1-6C alkyl), $-C(=O)NR^aR^b$ or benzyloxy;

R^a and R^b are independently H or (1-6C)alkyl;

n is 0, 1 or 2;

R^2 is H, F, Cl or CH_3;

R^3 is H, F or Cl;

R^4 is H, CN, F, Cl, Br, -OMe, $-OCF_3$, $-CF_3$, $-CH(OH)CH_2OH$ or $-C(=O)NH_2$;

R^5 is selected from:

H,

halogen,
CN,
OH,
$hetAr^4$,
$hetAr^5$,
$hetCyc^2$,
$hetCyc^3$(1-4Calkyl)-,
$hetCyc^4$(1-4C)alkoxy,
$hetCyc^5$(1-4C)alkoxy,
(1-3C alkoxy)(1-4C)alkoxy,
hydroxy(1-6C)alkoxy,
dihydroxy(2-6C)alkoxy,
(1-6C)alkoxy,
[hydroxy(2-4C)alkyl)amino]-(1-4C)alkyl,
[(1-4C alkoxy)(1-4C alkyl)amino](1-4C)alkyl,
[di(1-4C alkyl)amino](1-4C)alkyl,
(1-4C alkyl)C(=O)-,
hydroxy(1-6C)alkyl,
dihydroxy(2-6C)alkyl,
[di(1-3C alkyl)amino](1-4C)alkoxy,
N-(1-3C alkyl)pyridinone,
$hetAr^6$,
$hetCyc^6C(=O)$-,
($hetCyc^7$)-O-,
$hetCyc^8$(1-4C)alkoxy,
difluoroamino(1-4C)alkoxy,
[(1-4C alkoxy)carbonylamide]difluoro(1-4C)alkoxy,
(1-4C alkyl)C(=O)NH(2-4C)alkylthio-,
(1-4Calkyl)OC(=O)-, or
$R^cR^dNC(=O)$-;

$hetAr^4$ is a 5-membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein said ring is optionally substituted with one or more substituents independently selected from (1-6C)alkyl and [di(1-3C alkyl)amino]CH_2-;

$hetAr^5$ is a 6-membered heteroaryl ring having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetAr^6$ is a 9-membered partially unsaturated bicyclic heterocyclic ring having 3 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetCyc^2$ is a 5-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms selected from N and O, wherein said ring is optionally substituted with one or more substituents independently selected from (1-6C)alkyl, hydroxy(1-6C)alkyl, OH and oxo, provided said oxo is on a carbon atom;

$hetCyc^3$ is a 4-6 membered heterocyclic ring having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, (1-6C)alkoxy and halogen;

$hetCyc^4$ is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N, O and S, wherein one of said ring nitrogen atoms is optionally oxidized to N(O) and wherein said S ring atom is optionally oxidized to SO or SO_2, wherein $hetCyc^4$ is optionally substituted with one or more substituents independently selected from halogen, OH, (1-6C)alkyl, (1-4C alkoxy)(1-6C)alkyl, (1-4C)alkyl-OC(=O)- and (1-6C)alkoxy;

$hetCyc^5$ is a spiro heterocycle having 2 ring heteroatoms independently selected from N and O, wherein $hetCyc^5$ is optionally substituted with a group selected from (1-6C)alkyl;

$hetCyc^6$ is a 6 membered heterocyclic ring having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetCyc^7$ is a 4-6 membered heterocyclic ring having one or two ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl and OH;

$hetCyc^8$ is a bridged 8-membered heterocyclic ring having 2 ring atoms selected from N and O wherein at least one of said heteroatoms is N, wherein said ring is optionally substituted with (1-6C)alkyl;

R^c is H or (1-4C)alkyl;

R^d is (1-4C)alkyl, $hetCyc^{10}$-, amino(1-4C)alkyl, or [di(1-4C alkyl)amino](1-4C) alkyl;

hetCyc^{10} is a 5 membered heterocycle having a ring N atom and optionally substituted with one or more substituents independently selected from (1-6C)alkyl; and

R^6 is H or Cl.

2. A compound of claim 1, where R^1 is hetAr^1(CH$_2$)$_m$-, hetAr^{2}CH$_2$- or hetAr^{3}CH$_2$-.

3. A compound according to any of claims 1-2, where R^1 is hetAr^1(CH$_2$)$_m$-.

4. A compound according to any of claims 1-3, where m is 1.

5. A compound of claim 1, where R^1 is (3-6C cycloalkyl)-CH$_2$-, hetCyc^{1}CH$_2$-, Ar^1(CH$_2$)$_n$- or (N-1-3C alkyl)pyridinonyl-CH$_2$-.

6. A compound according to any of claims 1-5, where R^5 is selected from H, halogen, CN, OH, hetAr^4, hetAr^5, hetCyc^2, hetCyc^3(1-4Calkyl)-, hetCyc^4(1-4C)alkoxy, hetCyc^5(1-4C)alkoxy, (1-3C alkoxy)(1-4C)alkoxy, hydroxy(1-6C)alkoxy, dihydroxy(2-6C)alkoxy, (1-6C)alkoxy, [hydroxy(2-4C)alkyl)amino]-(1-4C)alkyl, [(1-4C alkoxy)(1-4C alkyl)amino](1-4C)alkyl, [di(1-4C alkyl)amino](1-4C)alkyl, (1-4C alkyl)C(=O)-, hydroxy(1-6C)alkyl, dihydroxy(2-6C)alkyl, [di(1-3C alkyl)amino](1-4C)alkoxy, and N-(1-3C alkyl)pyridinone.

7. A compound according to any of claims 1-6, where R^5 is selected from H, halogen, CN, and OH.

8. A compound according to any of claims 1-6, where R^5 is hetAr^4 or hetAr^5.

9. A compound according to any of claims 1-6, where R^5 is hetCyc^2 or hetCyc^3(1-4Calkyl)-.

10. A compound according to any of claims 1-6, where R^5 is hetCyc^4(1-4C)alkoxy or hetCyc^5(1-4C)alkoxy.

11. A compound according to claim 10, where R^5 is hetCyc^4(1-4C)alkoxy.

12. A compound according to any of claims 1-6, where R^5 is selected from (1-3C alkoxy)(1-4C)alkoxy, hydroxy(1-6C)alkoxy, dihydroxy(2-6C)alkoxy, (1-6C)alkoxy,[hydroxy(2-4C)alkyl)amino]-(1-4C)alkyl, [(1-4C alkoxy)(1-4C alkyl)amino](1-4C)alkyl, [di(1-4C alkyl)amino](1-4C)alkyl, (1-4C alkyl)C(=O)-, hydroxy(1-6C)alkyl, dihydroxy(2-6C)alkyl and [di(1-3C alkyl)amino](1-4C)alkoxy.

13. A compound according to any of claims 1-6, where R^5 is selected from N-(1-3C alkyl)pyridinone.

14. A compound according to any of claims 1-6, where R^5 is selected from $hetAr^6$, $hetCyc^6C(=O)$-, $(hetCyc^7)$-O-, $hetCyc^8$(1-4C)alkoxy, difluoroamino(1-4C)alkoxy, [(1-4C alkoxy)carbonylamide]difluoro(1-4C)alkoxy, (1-4C alkyl)C(=O)NH(2-4C)alkylthio-, (1-4Calkyl)OC(=O)-, and $R^cR^dNC(=O)$-.

15. A compound according to any of claims 1-14, where R^2 is H.

16. A compound according to any of claims 1-14, where R^2 is F or Cl.

17. A compound according to any of claims 1-14, where R^2 is CH_3.

18. A compound according to any of claims 1-17, where R^3 is H.

19. A compound according to any of claims 1-17, where R^3 is F or Cl.

20. A compound according to any of claims 1-19, where R^4 is H.

21. A compound according to any of claims 1-19, where R^4 is CN, Br, -OMe, -$CH(OH)CH_2OH$ or -$C(=O)NH_2$.

22. A compound according to any of claims 1-21, wherein R^6 is H.

23. A compound according to any of claims 1-21, wherein R^6 is Cl.

24. A compound selected from any one of Examples 1-161, or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition, which comprises a compound of Formula **I** as defined in any one of claims 1-24, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.


26. A method for treating a disease or disorder selected from bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, fibrosis , pain and burns in a mammal, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Formula **I** as defined in any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof.

27. The method according to claim 26, wherein said disease or disorder is fibrosis.

28. A compound of Formula **I** as defined in any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, for use in therapy.


29. A process for the preparation of a compound of claim 1, which comprises:

(a) coupling a corresponding compound of formula **II**



II


where Z^1 is COOH or a reactive derivative thereof with a corresponding compound of formula **III**



III


in the presence of a coupling reagent; or

(b) coupling a corresponding compound of formula **IV**



IV


with a compound of formula **III**



III

in the presence of a base; or


(c) for a compound of Formula **I** where R^5 is $hetCyc^4$(1-4C)alkoxy, ($hetCyc^7$)-O-, $hetCyc^8$(1-4C)alkoxy, hydroxy(1-6C)alkoxy, difluoroamino(1-4C)alkoxy, or [(1-4C alkoxy)carbonylamide]difluoro(1-4C)alkoxy, reacting a corresponding compound of formula **V**



V

where X^1 is F or Cl, with a compound having the formula R^{5a}-O- where R^{5a} is $hetCyc^4$(1-4C)alkyl-OH, $hetCyc^7$-OH, $hetCyc^8$(1-4C)alkyl-OH, P^1O-(1-6C)alkyl-OH, difluoroamino(1-4C)alkyl-OH or [(1-4C alkoxy)carbonylamide]difluoro(1-4C)alkyl-OH, respectively, in the presence of a base, where P^1 is a hydroxyl protecting group; or


(d) for a compound of Formula I where R^5 is $hetCyc^2$ where $hetCyc^2$ is a nitrogen radical, reacting a corresponding compound of formula **V-a**



V-a

with a compound having the formula $hetCyc^2$-H; or


(e) for a compound of Formula **I** where R^5 is $hetAr^4$ wherein $hetAr^4$ is a nitrogen radical, reacting a corresponding compound of formula **V-a**



V-a


with a compound having the formula $hetAr^4$-H in the presence of a base; or

(f) for a compound of Formula **I** where R^5 is a carbon linked substituent selected from $hetAr^4$, $hetAr^5$, and N-(1-3C alkyl)pyridinone, reacting a corresponding compound of formula **V-b**



V-b


with a compound having the formula **VI**



VI

where Ring E is a carbon-linked radical selected from $hetAr^4$, $hetAr^5$, and N-(1-3C alkyl)pyridinonyl, respectively, in the presence of a palladium catalyst and a base; or


(g) for a compound of Formula I where R^5 is $hetAr^4$ or $hetAr^6$ where $hetAr^4$ and $hetAr^6$ are carbon radicals, reacting a corresponding compound of formula **V-b**



V-b

with a compound having the formula $hetAr^4$-H or $hetAr^6$-H, respectively, in the presence of a palladium catalyst and a base and optionally in the presence of a ligand; or


(h) for a compound of Formula **I** where R^5 is $hetCyc^6C(=O)$-, reacting a corresponding compound having the formula **VII**




VII

with a compound having the formula $hetCyc^6$-H in the presence of a coupling reagent; or

(i) for a compound of Formula **I** where R^5 has the structure:




reacting a corresponding compound having the formula **VIII**




VIII

where R^{5b} is



respectively, with formaldehyde in the presence of a reducing agent; or


(j) for a compound of Formula **I** where R^5 is $R^cR^dNC(=O)$-, reacting a corresponding compound of formula **IX**




IX

with a compound having the formula R^cR^dNH in the presence of a coupling agent; or

(k) for a compound of Formula **I** wherein R^5 is an oxadiazole substituent having the formula:




where R^g is H or Me, cyclizing a corresponding compound having the formula **X**



X

in the presence of trimethoxymethane or triethoxyethane, respectively; or


(l) for a compound of Formula **I** wherein R^5 is 1,3,4-thiadiazol-2-yl, cyclizing a corresponding compound having the formula **XI**



XI

in the presence of P_2S_5; or


(m) for a compound of Formula **I** wherein R^5 is hetCyc^3(1-2Calkyl)- where hetCyc^{3}is a nitrogen radical, [(1-4C alkoxy)(1-4C alkyl)]amino(1-2C)alkyl, or [hydroxy(2-4C)alkyl)]amino-(1-2C)alkyl, reacting a corresponding compound of formula **XII**



XII

where n is 0 or 1 and Z is H or Me, with $hetCyc^3$-H, [(1-4C alkoxy)(1-4C alkyl)]NH_2 or [hydroxy(2-4C)alkyl)]NH_2, respectively, in the presence of a reducing agent; or


(n) for a compound of Formula **I** wherein R^1 is $hetAr^2CH_2$- and $hetAr^2$ is a pyrazolyl ring having a ring N atom substituted with a substituent selected from or (1-6C)alkyl-, reacting a corresponding compound having the formula **XIII**



XIII

with a compound having the formula (1-6C)alkyl-X^2, respectively, wherein X^2 is a leaving group or atom, in the presence of a base; or


(o) for a compound of Formula **I** wherein R^1 is N-(1-3C alkyl)pyridinonyl-CH_2- , coupling a corresponding compound having the formula **XIV**



XIV

with (1-3C alkyl)-L^1 where L^1 is a leaving group or atom in the presence of a base; or


(p) for a compound of Formula **I** wherein R^5 is $hetCyc^3CH_2$- where $hetCyc^3$ is a nitrogen radical, coupling a corresponding compound having the formula **XV**



XV

where L^2 is a leaving group with a compound having the formula $hetCyc^3$-H in the presence of a base; or


(q) for a compound of Formula **I** where R^5 is $hetCyc^4$(1-4C)alkoxy and $hetCyc^4$ is N-methylpiperazine-1-oxide, reacting a corresponding compound of formula **XVI**



XVI

where n is 0, 1, 2 or 3, with an oxidizing agent; or


(r) for a compound of Formula **I** wherein R^5 is $hetCyc^3(1\text{-}4Calkyl)$- where $hetCyc^3$is a nitrogen radical, reacting a corresponding compound having the formula **XVII**



XVII

where n is 0, 1, 2 or 3, and L^3 is a leaving group, with a corresponding compound having the formula $hetCyc^3$in the presence of a base; or


(s) for compound of Formula **I** where R^5 is (1-4C alkyl)C(=O)NH(2-4C)alkylthio-, coupling a corresponding compound having the formula **V**



V


where X^1 is F or Cl, with a compound having the formula (1-4C alkyl)C(=O)NH(2-4C)alkyl-SH in the presence of a base; or

(t) for a compound of Formula **I** wherein R^5 is $CH_2C(=O)$-, coupling a corresponding compound having the formula **V-b**




V-b

with a compound having the formula



in the presence of a palladium catalyst and a ligand, followed by treatment with acid; or

(u) for a compound of Formula **I** wherein R^5 is $HO(CH_2CH_2)$-, treating a corresponding compound having the formula **XVIII**




XVIII

with a reducing agent; and

removing any protecting groups if desired and forming a salt thereof if desired.

What is claimed is:

1. A compound having the general formula **I**



I

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is $hetAr^1(CH_2)_m$-, $hetAr^2CH_2$-, $hetAr^3CH_2$-, (3-6C cycloalkyl)-CH_2-, $hetCyc^1CH_2$-, $Ar^1(CH_2)_n$- or (N-1-3C alkyl)pyridinonyl-CH_2-;

$hetAr^1$ is a 6-membered heteroaryl having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, (1-4C)alkoxy, halogen, CF_3, or (3-6C)cycloalkyl;

m is 0, 1 or 2;

$hetAr^2$ is a 5-membered heteroaryl ring having 2-3 ring heteroatoms independently selected from N and S where at least one of said heteroatoms is N, wherein said ring is optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetAr^3$ is a bicyclic 5,6-fused heteroaryl ring having two ring nitrogen atoms;

$hetCyc^1$ is a 6-membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with -C(=O)(1-6C alkyl) or -C(=O)O(1-6C alkyl);

Ar^1 is phenyl optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkyl, CN, CF_3, OH, (1-6C)alkoxy, -C(=O)OH, -C(=O)O(1-6C alkyl), $-C(=O)NR^aR^b$ or benzyloxy;

R^a and R^b are independently H or (1-6C)alkyl;

n is 0, 1 or 2;

R^2 is H, F, Cl or CH_3;

R^3 is H, F or Cl;

R^4 is H, CN, F, Cl, Br, -OMe, $-OCF_3$, $-CF_3$, $-CH(OH)CH_2OH$ or $-C(=O)NH_2$;

R^5 is selected from:

H,

halogen,

CN,

OH,

$hetAr^4$,

$hetAr^5$,

$hetCyc^2$,

$hetCyc^3$(1-4Calkyl)-,

$hetCyc^4$(1-4C)alkoxy,

$hetCyc^5$(1-4C)alkoxy,

(1-3C alkoxy)(1-4C)alkoxy,

hydroxy(1-6C)alkoxy,

dihydroxy(2-6C)alkoxy,

(1-6C)alkoxy,

[hydroxy(2-4C)alkyl)amino]-(1-4C)alkyl,

[(1-4C alkoxy)(1-4C alkyl)amino](1-4C)alkyl,

[di(1-4C alkyl)amino](1-4C)alkyl,

(1-4C alkyl)C(=O)-,

hydroxy(1-6C)alkyl,

dihydroxy(2-6C)alkyl,

[di(1-3C alkyl)amino](1-4C)alkoxy,

N-(1-3C alkyl)pyridinone,

$hetAr^6$,

$hetCyc^6C(=O)$-,

$(hetCyc^7)$-O-,

$hetCyc^8$(1-4C)alkoxy,

difluoroamino(1-4C)alkoxy,

[(1-4C alkoxy)carbonylamide]difluoro(1-4C)alkoxy,

(1-4C alkyl)C(=O)NH(2-4C)alkylthio-,

(1-4Calkyl)OC(=O)-, or

$R^cR^dNC(=O)$-;

$hetAr^4$ is a 5-membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein said ring is optionally substituted with one or more substituents independently selected from (1-6C)alkyl and [di(1-3C alkyl)amino]CH_2-;

$hetAr^5$ is a 6-membered heteroaryl ring having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetAr^6$ is a 9-membered partially unsaturated bicyclic heterocyclic ring having 3 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetCyc^2$ is a 5-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms selected from N and O, wherein said ring is optionally substituted with one or more substituents independently selected from (1-6C)alkyl, hydroxy(1-6C)alkyl, OH and oxo, provided said oxo is on a carbon atom;

$hetCyc^3$ is a 4-6 membered heterocyclic ring having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, (1-6C)alkoxy and halogen;

$hetCyc^4$ is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N, O and S, wherein one of said ring nitrogen atoms is optionally oxidized to N(O) and wherein said S ring atom is optionally oxidized to SO or SO_2, wherein $hetCyc^4$ is optionally substituted with one or more substituents independently selected from halogen, OH, (1-6C)alkyl, (1-4C alkoxy)(1-6C)alkyl, (1-4C)alkyl-OC(=O)- and (1-6C)alkoxy;

$hetCyc^5$ is a spiro heterocycle having 2 ring heteroatoms independently selected from N and O, wherein $hetCyc^5$ is optionally substituted with a group selected from (1-6C)alkyl;

$hetCyc^6$ is a 6 membered heterocyclic ring having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetCyc^7$ is a 4-6 membered heterocyclic ring having one or two ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl and OH;

$hetCyc^8$ is a bridged 8-membered heterocyclic ring having 2 ring atoms selected from N and O wherein at least one of said heteroatoms is N, wherein said ring is optionally substituted with (1-6C)alkyl;

R^c is H or (1-4C)alkyl;

R^d is (1-4C)alkyl, $hetCyc^{10}$-, amino(1-4C)alkyl, or [di(1-4C alkyl)amino](1-4C) alkyl;

hetCyc^{10} is a 5 membered heterocycle having a ring N atom and optionally substituted with one or more substituents independently selected from (1-6C)alkyl; and

R^6 is H or Cl.

2. A compound of claim 1, where R^1 is hetAr^1(CH$_2$)$_m$-, hetAr^{2}CH$_2$- or hetAr^{3}CH$_2$-.

3. A compound according to any of claims 1-2, where R^1 is hetAr^1(CH$_2$)$_m$-.

4. A compound according to any of claims 1-3, where m is 1.

5. A compound of claim 1, where R^1 is (3-6C cycloalkyl)-CH$_2$-, hetCyc^{1}CH$_2$-, Ar^1(CH$_2$)$_n$- or (N-1-3C alkyl)pyridinonyl-CH$_2$-.

6. A compound according to any of claims 1-5, where R^5 is selected from H, halogen, CN, OH, hetAr^4, hetAr^5, hetCyc^2, hetCyc^3(1-4Calkyl)-, hetCyc^4(1-4C)alkoxy, hetCyc^5(1-4C)alkoxy, (1-3C alkoxy)(1-4C)alkoxy, hydroxy(1-6C)alkoxy, dihydroxy(2-6C)alkoxy, (1-6C)alkoxy, [hydroxy(2-4C)alkyl)amino]-(1-4C)alkyl, [(1-4C alkoxy)(1-4C alkyl)amino](1-4C)alkyl, [di(1-4C alkyl)amino](1-4C)alkyl, (1-4C alkyl)C(=O)-, hydroxy(1-6C)alkyl, dihydroxy(2-6C)alkyl, [di(1-3C alkyl)amino](1-4C)alkoxy, and N-(1-3C alkyl)pyridinone.

7. A compound according to any of claims 1-6, where R^5 is selected from H, halogen, CN, and OH.

8. A compound according to any of claims 1-6, where R^5 is hetAr^4 or hetAr^5.

9. A compound according to any of claims 1-6, where R^5 is hetCyc^2 or hetCyc^3(1-4Calkyl)-.

10. A compound according to any of claims 1-6, where R^5 is hetCyc^4(1-4C)alkoxy or hetCyc^5(1-4C)alkoxy.

11. A compound according to claim 10, where R^5 is hetCyc^4(1-4C)alkoxy.

12. A compound according to any of claims 1-6, where R^5 is selected from (1-3C alkoxy)(1-4C)alkoxy, hydroxy(1-6C)alkoxy, dihydroxy(2-6C)alkoxy, (1-6C)alkoxy,[hydroxy(2-4C)alkyl)amino]-(1-4C)alkyl, [(1-4C alkoxy)(1-4C alkyl)amino](1-4C)alkyl, [di(1-4C alkyl)amino](1-4C)alkyl, (1-4C alkyl)C(=O)-, hydroxy(1-6C)alkyl, dihydroxy(2-6C)alkyl and [di(1-3C alkyl)amino](1-4C)alkoxy.

13. A compound according to any of claims 1-6, where R^5 is selected from N-(1-3C alkyl)pyridinone.

14. A compound according to any of claims 1-6, where R^5 is selected from $hetAr^6$, $hetCyc^6C(=O)$-, $(hetCyc^7)$-O-, $hetCyc^8$(1-4C)alkoxy, difluoroamino(1-4C)alkoxy, [(1-4C alkoxy)carbonylamide]difluoro(1-4C)alkoxy, (1-4C alkyl)C(=O)NH(2-4C)alkylthio-, (1-4Calkyl)OC(=O)-, and $R^cR^dNC(=O)$-.

15. A compound according to any of claims 1-14, where R^2 is H.

16. A compound according to any of claims 1-14, where R^2 is F or Cl.

17. A compound according to any of claims 1-14, where R^2 is CH_3.

18. A compound according to any of claims 1-17, where R^3 is H.

19. A compound according to any of claims 1-17, where R^3 is F or Cl.

20. A compound according to any of claims 1-19, where R^4 is H.

21. A compound according to any of claims 1-19, where R^4 is CN, Br, -OMe, -$CH(OH)CH_2OH$ or -$C(=O)NH_2$.

22. A compound according to any of claims 1-21, wherein R^6 is H.

23. A compound according to any of claims 1-21, wherein R^6 is Cl.


24. A compound selected from any one of Examples 1-161, or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition, which comprises a compound of Formula **I** as defined in any one of claims 1-24, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

26. A compound of Formula **I** as defined in any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, for use in therapy.


27. A process for the preparation of a compound of claim 1, which comprises:

(a) coupling a corresponding compound of formula **II**



II


where Z^1 is COOH or a reactive derivative thereof with a corresponding compound of formula **III**



III


in the presence of a coupling reagent; or

(b) coupling a corresponding compound of formula **IV**



IV


with a compound of formula **III**



III

in the presence of a base; or


(c) for a compound of Formula **I** where R^5 is hetCyc^4(1-4C)alkoxy, (hetCyc^7)-O-, hetCyc^8(1-4C)alkoxy, hydroxy(1-6C)alkoxy, difluoroamino(1-4C)alkoxy, or [(1-4C alkoxy)carbonylamide]difluoro(1-4C)alkoxy, reacting a corresponding compound of formula **V**



V

where X^1 is F or Cl, with a compound having the formula R^{5a}-O- where R^{5a} is hetCyc^4(1-4C)alkyl-OH, hetCyc^7-OH, hetCyc^8(1-4C)alkyl-OH, P^1O-(1-6C)alkyl-OH, difluoroamino(1-4C)alkyl-OH or [(1-4C alkoxy)carbonylamide]difluoro(1-4C)alkyl-OH, respectively, in the presence of a base, where P^1 is a hydroxyl protecting group; or


(d) for a compound of Formula **I** where R^5 is $hetCyc^2$ where $hetCyc^2$ is a nitrogen radical, reacting a corresponding compound of formula **V-a**



V-a

with a compound having the formula $hetCyc^2$-H; or


(e) for a compound of Formula **I** where R^5 is $hetAr^4$ wherein $hetAr^4$ is a nitrogen radical, reacting a corresponding compound of formula **V-a**



V-a


with a compound having the formula $hetAr^4$-H in the presence of a base; or

(f) for a compound of Formula **I** where R^5 is a carbon linked substituent selected from $hetAr^4$, $hetAr^5$, and N-(1-3C alkyl)pyridinone, reacting a corresponding compound of formula **V-b**



V-b


with a compound having the formula **VI**



VI

where Ring E is a carbon-linked radical selected from $hetAr^4$, $hetAr^5$, and N-(1-3C alkyl)pyridinonyl, respectively, in the presence of a palladium catalyst and a base; or


(g) for a compound of Formula **I** where R^5 is $hetAr^4$ or $hetAr^6$ where $hetAr^4$ and $hetAr^6$ are carbon radicals, reacting a corresponding compound of formula **V-b**



V-b

with a compound having the formula $hetAr^4$-H or $hetAr^6$-H, respectively, in the presence of a palladium catalyst and a base and optionally in the presence of a ligand; or


(h) for a compound of Formula **I** where R^5 is $hetCyc^6C(=O)$-, reacting a corresponding compound having the formula **VII**




VII

with a compound having the formula $hetCyc^6$-H in the presence of a coupling reagent; or

(i) for a compound of Formula **I** where R^5 has the structure:




reacting a corresponding compound having the formula **VIII**




VIII

where R^{5b} is



respectively, with formaldehyde in the presence of a reducing agent; or


(j) for a compound of Formula **I** where R^5 is $R^cR^dNC(=O)$-, reacting a corresponding compound of formula **IX**




IX

with a compound having the formula R^cR^dNH in the presence of a coupling agent; or

(k) for a compound of Formula I wherein R^5 is an oxadiazole substituent having the formula:




where R^g is H or Me, cyclizing a corresponding compound having the formula X



X

in the presence of trimethoxymethane or triethoxyethane, respectively; or


(l) for a compound of Formula I wherein R^5 is 1,3,4-thiadiazol-2-yl, cyclizing a corresponding compound having the formula XI



XI

in the presence of P_2S_5; or


(m) for a compound of Formula I wherein R^5 is $hetCyc^3$(1-2Calkyl)- where $hetCyc^3$is a nitrogen radical, [(1-4C alkoxy)(1-4C alkyl)]amino(1-2C)alkyl, or [hydroxy(2-4C)alkyl)]amino-(1-2C)alkyl, reacting a corresponding compound of formula XII



XII

where n is 0 or 1 and Z is H or Me, with $hetCyc^3$-H, [(1-4C alkoxy)(1-4C alkyl)]NH_2 or [hydroxy(2-4C)alkyl)]NH_2, respectively, in the presence of a reducing agent; or


(n) for a compound of Formula **I** wherein R^1 is $hetAr^2CH_2$- and $hetAr^2$ is a pyrazolyl ring having a ring N atom substituted with a substituent selected from or (1-6C)alkyl-, reacting a corresponding compound having the formula **XIII**



XIII

with a compound having the formula (1-6C)alkyl-X^2, respectively, wherein X^2 is a leaving group or atom, in the presence of a base; or


(o) for a compound of Formula **I** wherein R^1 is N-(1-3C alkyl)pyridinonyl-CH_2- , coupling a corresponding compound having the formula **XIV**



XIV

with (1-3C alkyl)-L^1 where L^1 is a leaving group or atom in the presence of a base; or


(p) for a compound of Formula **I** wherein R^5 is $hetCyc^3CH_2$- where $hetCyc^3$ is a nitrogen radical, coupling a corresponding compound having the formula **XV**



XV

where L^2 is a leaving group with a compound having the formula $hetCyc^3$-H in the presence of a base; or


(q) for a compound of Formula **I** where R^5 is $hetCyc^4$(1-4C)alkoxy and $hetCyc^4$ is N-methylpiperazine-1-oxide, reacting a corresponding compound of formula **XVI**



XVI

where n is 0, 1, 2 or 3, with an oxidizing agent; or


(r) for a compound of Formula **I** wherein R^5 is $hetCyc^3$(1-4Calkyl)- where $hetCyc^3$is a nitrogen radical, reacting a corresponding compound having the formula **XVII**



XVII

where n is 0, 1, 2 or 3, and L^3 is a leaving group, with a corresponding compound having the formula $hetCyc^3$in the presence of a base; or


(s) for compound of Formula **I** where R^5 is (1-4C alkyl)C(=O)NH(2-4C)alkylthio-, coupling a corresponding compound having the formula **V**



V


where X^1 is F or Cl, with a compound having the formula (1-4C alkyl)C(=O)NH(2-4C)alkyl-SH in the presence of a base; or

(t) for a compound of Formula **I** wherein R^5 is $CH_3C(=O)$-, coupling a corresponding compound having the formula **V-b**




V-b

with a compound having the formula



in the presence of a palladium catalyst and a ligand, followed by treatment with acid; or

(u) for a compound of Formula **I** wherein R^5 is $HO(CH_2CH_2)$-, treating a corresponding compound having the formula **XVIII**



XVIII

with a reducing agent; and

removing any protecting groups if desired and forming a salt thereof if desired.